Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 (IgG4) antibody, imsidolimab, to treat ...

More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), ...

The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...

Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue.1,2,3,4SPEVIGO's ...

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis <li /> Vanda expects to immediately ...

are now available in Canada for the treatment of generalized pustular psoriasis (GPP) in patients 12 years of age and older, weighing at least 40 kg. 5 The subcutaneous formulation for chronic GPP ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...